In individuals with T2D, retatrutide resulted in a decrease in HbA1c of up to −2.02% compared to −0.01% for placebo and −1.41% for the selective GLP-1R agonist dulaglutide, demonstrating that in the context of GLP-1R and GIPR agonism, activation of glucagon receptors does not impair glycemic control [1002]. Here, GIPR is linked to type 2 diabetes mellitus.